This is a staging instance. Full-text downloads are disabled.
 

Publication:
Host transcriptomic profiling of COVID-19 patients with mild, moderate, and severe clinical outcomes

dc.contributor.authorUddin, Mohammed
dc.contributor.authorLoney, Tom
dc.contributor.authorNowotny, Norbert
dc.contributor.authorAlsuwaidi, Hanan
dc.contributor.authorAlsheikh-Ali, Alawi
dc.contributor.authorTayoun, Ahmad Abou
dc.date.accessioned2022-02-22T04:36:53Z
dc.date.available2022-02-22T04:36:53Z
dc.date.issued2021
dc.description.abstractAbstract: Characterizing key molecular and cellular pathways involved in COVID-19 is essential for disease prognosis and management. We perform shotgun transcriptome sequencing of human RNA obtained from nasopharyngeal swabs of patients with COVID-19, and identify a molecular signature associated with disease severity. Specifically, we identify globally dysregulated immune related pathways, such as cytokinecytokine receptor signaling, complement and coagulation cascades, JAK-STAT, and TGF- b signaling pathways in all, though to a higher extent in patients with severe symptoms. The excessive release of cytokines and chemokines such as CCL2, CCL22, CXCL9 and CXCL12 and certain interferons and interleukins related genes like IFIH1, IFI44, IFIT1 and IL10 were significantly higher in patients with severe clinical presentation compared to mild and moderate presentations. Differential gene expression analysis identified a small set of regulatory genes that might act as strong predictors of patient outcome. Our data suggest that rapid transcriptome analysis of nasopharyngeal swabs can be a powerful approach to quantify host molecular response and may provide valuable insights into COVID-19 pathophysiology.en_US
dc.identifier.other204-2021.142
dc.identifier.urihttps://repository.mbru.ac.ae/handle/1/853
dc.language.isoenen_US
dc.subjectTranscriptome sequencingen_US
dc.subjectCOVID-19en_US
dc.subjectDisease severityen_US
dc.subjectExpression signatureen_US
dc.subjectNasopharyngeal swabsen_US
dc.titleHost transcriptomic profiling of COVID-19 patients with mild, moderate, and severe clinical outcomesen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files